Summer Series: CSL Limited (ASX: CSL)

Welcome to the Equity Mates Summer Series of 2020 brought to you by Superhero.Over 12 episodes we dive into some of Australia’s largest and most well-known companies, as selected by you, the Equity Mates community.In this episode, we unpack CSL - one of the market darlings on the ASX. CSL Limited is a global specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions.In each episode we look at:A company summaryThe industryTheir competitionThe outlook and future plansKey financialsValuationFor some of the companies, we've been lucky enough to get access to the CEO, where we take some of the tough questions straight to them.Superhero offers unlimited $5 trades on ASX-listed shares. For more information or to sign-up, head to their website here*****Any views expressed by the podcast host or any guest are their own and do not represent the views of Equity Mates Media or any other employer or associated organisation.Always remember, all information contained in this podcast is for education and entertainment purposes only. It is not intended as a substitute for professional financial, legal or tax advice. The hosts of Equity Mates are not financial professionals and are not aware of your personal financial circumstances. Before making any financial decisions you should read the Produce Disclosure Statement (PDS) and, if necessary, consult a licensed financial professional.For more information head to our Disclaimer Page, where you can find resources to search for a registered financial professional near you.*****Have you just started your investing journey? Head over to Get Started Investing – Equity Mates 12-part series with all the fundamentals you need to feel confident to start your investing journey.Want more Equity Mates? Subscribe to Equity Mates Investing Podcast, social media channels, Thought Starters mailing list and more here. Hosted on Acast. See acast.com/privacy for more information.

There are no comments yet.

Please log in to write the first comment.